Cowen and Company reiterated their outperform rating on shares of Johnson & Johnson (NYSE:JNJ) in a report released on Wednesday, October 18th, The Fly reports. They currently have a $155.00 price objective on the stock, up from their prior price objective of $147.00.
Other analysts have also recently issued research reports about the stock. J P Morgan Chase & Co upped their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an overweight rating in a research note on Wednesday, August 16th. BTIG Research cut shares of Johnson & Johnson from a neutral rating to a sell rating and set a $110.00 target price on the stock. in a research note on Friday, July 21st. UBS AG reissued a buy rating and issued a $148.00 target price (up previously from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Wells Fargo & Company reissued a market perform rating and issued a $135.00 target price (up previously from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th. Finally, Jefferies Group LLC set a $145.00 price objective on shares of Johnson & Johnson and gave the stock a hold rating in a research note on Tuesday, August 15th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of Hold and an average price target of $143.70.
Shares of Johnson & Johnson (JNJ) traded down 0.02% during midday trading on Wednesday, hitting $141.78. The stock had a trading volume of 5,140,654 shares. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35. The stock has a 50-day moving average price of $135.26 and a 200-day moving average price of $131.38. The stock has a market cap of $380.54 billion, a P/E ratio of 24.66 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.68%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.68 EPS. Equities analysts forecast that Johnson & Johnson will post $7.28 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/johnson-johnsons-jnj-outperform-rating-reaffirmed-at-cowen-and-company.html.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.37%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
Hedge funds have recently modified their holdings of the company. OLD Point Trust & Financial Services N A increased its position in shares of Johnson & Johnson by 2.2% during the second quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after acquiring an additional 1,321 shares in the last quarter. Lynch & Associates IN increased its position in shares of Johnson & Johnson by 0.9% during the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after acquiring an additional 841 shares in the last quarter. Oakbrook Investments LLC increased its position in shares of Johnson & Johnson by 7.4% during the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after acquiring an additional 9,375 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Johnson & Johnson during the first quarter worth $1,731,000. Finally, Bollard Group LLC increased its position in shares of Johnson & Johnson by 5.0% during the second quarter. Bollard Group LLC now owns 9,551 shares of the company’s stock worth $1,263,000 after acquiring an additional 459 shares in the last quarter. 65.89% of the stock is owned by institutional investors.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.